IMARC Group has recently released a newresearch study titled “United States Animal Health Market Size, Share,Trends and Forecast by Animal Type, Product Type, and Region, 2026-2034,”offers a detailed analysis of the market drivers, segmentation, growthopportunities, trends and competitive landscape to understand the current andfuture market scenarios.
United States Animal Health Market Size,Growth, and Forecast (2026-2034)
unitedstates animal health market size reached USD 20.92 Billion in 2025 and isprojected to reach USD 47.65 Billion by 2034, growing at a CAGR of 9.58% during2026-2034. Rising pet ownership, growing livestock disease burden, andadvancements in veterinary diagnostics and biologicals are the primary factorsdriving the market.
Animal health encompasses the development,manufacture, and commercialization of pharmaceuticals, biologicals,diagnostics, and medicated feed additives for both commercial livestock andcompanion animals. The market expanded from USD 13.24 Billion in 2020 to USD20.92 Billion in 2025, with sustained demand for companion animal healthcareand increasing adoption of preventive veterinary products underpinningabove-trend growth.
Diagnostics represents the fastest-growingproduct category at approximately 12.1% CAGR through rapid point-of-caretesting adoption, while biologicals follow at approximately 11.2% CAGR as novelvaccine platforms, including mRNA technology, transform preventive care acrossboth livestock and companion animal segments.
Explore GrowthOpportunities in the United States Animal Health Market - Grab Your SampleReport for Evaluation: https://www.imarcgroup.com/united-states-animal-health-market/requestsample
Key Trends Driving the United States AnimalHealth Market
• Growing pet ownership increasing demand forcompanion animal healthcare: Rising pet ownership across the United Statesis driving sustained demand for veterinary pharmaceuticals, preventive care,and diagnostics, with greater humanization of pets increasing average per-pethealthcare spending.
• Rising livestock disease burden drivingveterinary pharmaceutical adoption: Increasing incidence of livestock diseasessuch as bovine respiratory disease, swine influenza, and avian influenza isdriving demand for vaccines, antibiotics, and biosecurity products across largecommercial operations.
• Technological advancements in veterinarydiagnostics and biologicals: Advances in molecular diagnostics, PCR-basedpathogen detection, and point-of-care testing are expanding diagnostic marketopportunities, while novel mRNA vaccine platforms are creating new biologicalproduct categories.
• Increasing awareness of zoonotic diseases andOne Health initiatives: Growing recognition of the links betweenanimal, human, and environmental health is driving investment in veterinarysurveillance, diagnostics, and preventive care, supported by increased federaland state funding.
United States Animal Health Market ReportSegmentation:
The United States Animal Health Market reportprovides a detailed segmentation analysis to help businesses identify keygrowth segments and evolving industry dynamics. The market is categorized basedon animal type, product type, and region, offering comprehensive insightsacross the united states animal health market.
Animal Type Insights:
• Commercial: Commercial animals leadthe market with a 61.8% share in 2025, driven by the scale of US livestock,poultry, and aquaculture industries and the critical need for diseaseprevention and growth promotion across herd health protocols.
• Companion: Companion animals accountfor 38.2% of the market and represent the fastest-growing segment, supported byrising pet ownership, increasing humanization of pets, and growing veterinaryspending per animal.
Product Type Insights:
• Pharmaceuticals: Pharmaceuticalslead the market with a 42.7% share in 2025, encompassing antibiotics,antiparasitics, anti-inflammatory drugs, hormones, and anesthetics used acrossboth commercial and companion animal healthcare.
• Biologicals: Biologicalshold a 28.4% share and encompass vaccines, immunostimulants, and emergingimmunotherapy products, supported by growing adoption of novel vaccineplatforms.
• Medicinal Feed Additives: Medicinalfeed additives hold a 17.3% share, though the category faces structuralpressure from antimicrobial stewardship regulations limiting preventiveantibiotic use in food animals.
• Diagnostics: Diagnosticshold an 11.6% share and represent the fastest-growing category at approximately12.1% CAGR, driven by rapid point-of-care testing adoption in both clinic andfarm settings.
Regional Insights:
• Midwest: The Midwest leads themarket with a 32.5% share, anchored by its high concentration of cattlefeedlots, swine confinement operations, and poultry production infrastructurerequiring intensive health management.
• South: The South holds a 30.9%share, supported by large-scale beef cattle and broiler production acrossstates such as Texas, Arkansas, Georgia, and Alabama, alongside a growingcompanion animal market in urban centers.
• West: The West accounts for a20.1% share, driven by California's dominant dairy industry and a strongcompanion animal market across Los Angeles, San Francisco, and Seattle.
• Northeast: The Northeast holds a16.5% share, representing the highest companion animal healthcare spending perowner, driven by premium veterinary service adoption and specialty referralcenters.
United States Animal Health Market: RecentNews and Developments
March 2026: Zoetisannounced that its Vetscan OptiCell platform was named “Best New CompanionAnimal Product” by S&P Global Animal Health for 2025, recognizing thecompany's continued innovation in veterinary diagnostics and companion animalcare.
June 2026: MerckAnimal Health announced a definitive agreement to acquire TARGAN, an animalAgTech company specializing in poultry biodevice technologies, expanding itspoultry portfolio through the WingScan automated chick gender-identificationsystem and precision ocular spray vaccine administration technology.
Challenges Impacting the United States AnimalHealth Market
High costs of advanced veterinary treatments,diagnostics, and specialty pharmaceuticals create access barriers forsmall-scale producers and rural pet owners, compounded by limited veterinaryinfrastructure in rural regions.
Stringent regulatory approval pathways fromthe FDA Center for Veterinary Medicine and USDA APHIS, along with growingregulatory restrictions on antibiotic use in food animals, are increasingcompliance costs and constraining pharmaceutical revenue in key livestocksegments.
Investment Opportunities in the United StatesAnimal Health Market
The united states animal health marketpresents compelling investment opportunities supported by its projected growthfrom USD 20.92 Billion in 2025 to USD 47.65 Billion by 2034. mRNA and novelvaccine platforms represent a high-value opportunity, with companiesestablishing manufacturing capability and regulatory expertise by 2026-2027positioned to capture the commercial deployment wave.
Companion animal diagnostics subscriptionrevenue models also represent a growing investment frontier, combining hardwareplacement with recurring reagent and software subscription revenue. Rising petinsurance penetration is further increasing willingness to pay for advanceddiagnostics and specialty pharmaceuticals.
Outlook of the United States Animal HealthMarket (2026-2034)
The outlook for the united states animalhealth market is positive, supported by growing companion animal ownership,rising healthcare spending per pet, and the technology transition towardAI-assisted, connected, continuous monitoring. The market is projected to growfrom USD 20.92 Billion in 2025 to USD 47.65 Billion by 2034 at a CAGR of 9.58%,with an anchor value of approximately USD 33.05 Billion expected by 2030.
Continued adoption of mRNA veterinaryvaccines, expansion of AI-powered diagnostic imaging, and regulatory evolutionaround antimicrobial stewardship will be the defining trends shaping the unitedstates animal health market through 2034.
Key Players in the United States Animal HealthMarket
The united states animal health market ismoderately concentrated at the top, with the five largest companiescollectively accounting for approximately 65-70% of national market revenuethrough broad product portfolios and deep R&D investment.
Zoetis Services LLC: Theworld's largest animal health company, Zoetis offers the broadest portfolio ofveterinary medicines, vaccines, and diagnostic products for companion andcommercial animals, with US operations centered in Parsippany, New Jersey, andkey products including Draxxin, Simparica Trio, and the Vanguard vaccine line.
Merck & Co. Inc.: Aleading provider of veterinary vaccines, pharmaceuticals, and health managementsolutions, Merck Animal Health holds strong positions in both companion animaland livestock health categories, with key products including NuFlor, theNobivac vaccine line, and Bravecto.
Frequently Asked Questions (FAQs): UnitedStates Animal Health Market
1. What is the currentUnited States animal health market size?
The United States animal health market sizereached USD 20.92 Billion in 2025 and is projected to reach USD 47.65 Billionby 2034, growing at a CAGR of 9.58% during 2026-2034.
2. What products areincluded in the United States animal health market?
The market encompasses pharmaceuticals,biologicals, diagnostics, and medicinal feed additives supporting the health ofboth commercial livestock and companion animals.
3. What are the keydrivers of the united states animal health market?
Key drivers include growing pet ownership,rising livestock disease burden, technological advancements in veterinarydiagnostics and biologicals, and increasing awareness of zoonotic diseases andOne Health initiatives.
4. Which animal typeleads the United States animal health market?
Commercial animals lead the united statesanimal health market with a 61.8% share in 2025, driven by the scale of USlivestock, poultry, and aquaculture operations.
5. Who are the keyplayers in the United States animal health market?
Key players in the united states animal healthmarket include Zoetis Services LLC and Merck & Co. Inc., alongside othercompanies such as Elanco and Boehringer Ingelheim International GmbH.
Author IMARC Group
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
United States: +1-201971-6302
